Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:
Joleen Hubbard, MD
John L. Marshall, MD
Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Latest data on nivolumab plus chemotherapy or ipilimumab for untreated advanced esophageal cancer (CheckMate 648) from ASCO 2021 reported by Clinical Care Options (CCO)
Data from ASCO 2021 on the CheckMate 649 trial of first-line nivolumab + chemotherapy for gastroesophageal cancer, as reported by Clinical Care Options (CCO)
Get a preview of key studies being presented at ASCO 2021 from experts in solid tumors and hematologic malignancies from Clinical Care Options (CCO)
Expert video on new and established therapies targeting HER2/HER3 in gastrointestinal cancers, from Clinical Care Options (CCO)